NEW YORK, Sept. 17, 2012 /PRNewswire/ -- Citeline®, an Informa business, reviewed clinical trial data presented at the European Respiratory Society (ERS) conference, held September 1-5, 2012 in Vienna, Austria, noting that classical fixed-dose combination (FDC) treatments remain a focus of industry sponsors, but that novel targeted asthma drugs may also be on the horizon for persistent asthma patients.
Respiratory drug leader GSK presented largely positive results from five pivotal Relvar (formerly Relovair) asthma trials. The results, submitted in July as part of the company's regulatory filing for asthma in the EU, demonstrated improved efficacy and safety. Citeline's Trialtrove® database monitors the development of these novel, once-daily drugs for asthma, and notes that Novartis/Merck's QMF149 program is the closest competitor behind Relvar. However, since the QMF149 program is still in phase II trials and is shifting development to the Breezhaler device, a long road remains before regulatory submission, promising Relvar a spot as the only marketed once-daily inhaled corticosteroid/long-acting beta agonist (ICS/LABA) following its approval.
"In addition to these novel therapies, Trialtrove also monitors generic FDC development, and found the majority of ongoing phase III asthma trials are for generic FDCs administered using new delivery devices, such as Chiesi's NEXThaler, Orion Pharma's Easyhaler and Vectura's Gyrohaler. The classical FDC treatment paradigm remains highly effective for many asthma patients, and more affordable generic versions of these drugs will present strong competition for blockbusters Advair and Symbicort," states Dr. Laura Runkel, Citeline's Associate Director of Autoimmune/Inflammation.
Trialtrove data tracks biologics in
Copyright©2012 PR Newswire.
All rights reserved